TABLE 3.
Treatment Effects for All Contrasts in Terms of OR of ACR20 Response Along with 95% CrI and Probability That Treatment Is Better Than Comparator
| Intervention | Comparator | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Placebo + MTX | aTNF | TOF 5 mg | TCZ | ABT + MTX | ANA + MTX | aTNF + MTX | TOF 5 mg + MTX | TCZ + MTX | ||
| Placebo | OR (95% CrI) |
1 (1, 1) |
0.26 (0.05, 1.34) |
0.15 (0.08, 0.29) |
0.21 (0.10, 0.47) |
0.08 (0.02, 0.25) |
0.07 (0.01, 0.40) |
0.12 (0.02, 0.82) |
0.06 (0.01, 0.33) |
0.09 (0.01, 0.48) |
0.07 (0.01, 0.32) |
| P(better) | NA | 0.05 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | 0.02 | < 0.01 | < 0.01 | < 0.01 | |
| Placebo + MTX | OR (95% CrI) |
3.80 (0.75, 20.53) |
1.00 (1, 1) |
0.57 (0.13, 2.68) |
0.80 (0.14, 5.40) |
0.30 (0.09, 0.97) |
0.28 (0.17, 0.46) |
0.46 (0.17, 1.24) |
0.24 (0.18, 0.32) |
0.33 (0.18, 0.59) |
0.27 (0.14, 0.55) |
| P(better) | 0.95 | NA | 0.23 | 0.40 | 0.02 | < 0.01 | 0.06 | < 0.01 | < 0.01 | < 0.01 | |
| aTNF | OR (95% CrI) |
6.67 (3.48, 13.08) |
1.75 (0.37, 7.97) |
1.00 (1, 1) |
1.41 (0.51, 4.08) |
0.52 (0.19, 1.41) |
0.48 (0.10, 2.41) |
0.79 (0.12, 5.02) |
0.41 (0.09, 1.94) |
0.57 (0.11, 2.94) |
0.48 (0.12, 1.88) |
| P(better) | > 0.99 | 0.77 | NA | 0.75 | 0.09 | 0.18 | 0.4 | 0.13 | 0.24 | 0.14 | |
| TOF 5 mg | OR (95% CrI) |
4.72 (2.11, 10.33) |
1.24 (0.19, 7.34) |
0.71 (0.24, 1.96) |
1.00 (1, 1) |
0.37 (0.08, 1.48) |
0.34 (0.05, 2.22) |
0.56 (0.07, 4.45) |
0.29 (0.04, 1.77) |
0.41 (0.06, 2.68) |
0.34 (0.06, 1.78) |
| P(better) | > 0.99 | 0.60 | 0.25 | NA | 0.08 | 0.13 | 0.29 | 0.09 | 0.17 | 0.10 | |
| TCZ | OR (95% CrI) |
12.89 (3.96, 44.39) |
3.38 (1.03, 11.17) |
1.94 (0.71, 5.36) |
2.74 (0.68, 12.11) |
1.00 (1, 1) |
0.94 (0.26, 3.43) |
1.55 (0.33, 7.54) |
0.80 (0.23, 2.74) |
1.10 (0.30, 4.22) |
0.92 (0.35, 2.48) |
| P(better) | > 0.99 | 0.98 | 0.91 | 0.92 | NA | 0.46 | 0.72 | 0.35 | 0.56 | 0.43 | |
| ABT + MTX | OR (95% CrI) |
13.72 (2.49, 79.12) |
3.60 (2.18, 5.96) |
2.06 (0.41, 10.45) |
2.91 (0.45, 20.52) |
1.06 (0.29, 3.86) |
1.00 (1, 1) |
1.64 (0.54, 5.04) |
0.85 (0.51, 1.43) |
1.17 (0.56, 2.55) |
0.99 (0.42, 2.32) |
| P(better) | > 0.99 | > 0.99 | 0.82 | 0.87 | 0.54 | NA | 0.82 | 0.26 | 0.67 | 0.49 | |
| ANA + MTX | OR (95% CrI) |
8.37 (1.22, 59.84) |
2.19 (0.80, 5.98) |
1.26 (0.20, 8.02) |
1.77 (0.22, 15.29) |
0.64 (0.13, 3.06) |
0.61 (0.20, 1.87) |
1.00 (1, 1) |
0.52 (0.18, 1.49) |
0.71 (0.22, 2.29) |
0.60 (0.18, 2.10) |
| P(better) | 0.98 | 0.94 | 0.6 | 0.71 | 0.28 | 0.18 | NA | 0.10 | 0.27 | 0.19 | |
| aTNF + MTX | OR (95% CrI) |
16.06 (3.07, 88.89) |
4.22 (3.17, 5.69) |
2.41 (0.51, 11.61) |
3.40 (0.56, 23.22) | 1.25 (0.37, 4.27) |
1.17 (0.70, 1.98) |
1.93 (0.67, 5.51) |
1.00 (1, 1) |
1.37 (0.74, 2.59) |
1.16 (0.55, 2.51) |
| P(better) | > 0.99 | > 0.99 | 0.87 | 0.91 | 0.65 | 0.74 | 0.90 | NA | 0.86 | 0.66 | |
| TOF 5 mg + MTX | OR (95% CrI) |
11.66 (2.07, 68.81) |
3.08 (1.70, 5.46) |
1.75 (0.34, 9.07) |
2.46 (0.37, 17.67) |
0.91 (0.24, 3.38) |
0.86 (0.39, 1.80) |
1.40 (0.44, 4.45) |
0.73 (0.39, 1.34) |
1.00 (1, 1) |
0.84 (0.34, 2.09) |
| P(better) | > 0.99 | > 0.99 | 0.76 | 0.83 | 0.44 | 0.33 | 0.73 | 0.14 | NA | 0.34 | |
| TCZ + MTX | estimate (95% CrI) |
13.86 (3.11, 66.90) |
3.65 (1.81, 7.36) |
2.09 (0.53, 8.35) |
2.93 (0.56, 17.34) |
1.08 (0.40, 2.84) |
1.01 (0.43, 2.41) |
1.66 (0.48, 5.66) |
0.86 (0.40, 1.83) |
1.18 (0.48, 2.97) |
1.00 (1, 1) |
| P(better) | > 0.99 | > 0.99 | 0.86 | 0.90 | 0.57 | 0.51 | 0.81 | 0.34 | 0.66 | NA | |
ABT = abatacept; ACR20 = 20% improvement in American College of Rheumatology criteria; ANA = anakinra; aTNF = anti-tumor necrosis factor; CrI = credible interval; mg = milligram; MTX = methotrexate; NA = not applicable; OR = odds ratio; P(better) = probability that treatment (in row) is showing greater response than comparator (in column); TCZ = tocilizumab; TOF = tofacitinib.